Login / Signup

AurkA nuclear localization is promoted by TPX2 and counteracted by protein degradation.

Italia Anna AsteritiFederica PolverinoVenturina StagniValentina SterbiniCamilla AscanelliFrancesco Davide NasoAnna MastrangeloAlessandro RosaAlessandro PaiardiniCatherine LindonGiulia Guarguaglini
Published in: Life science alliance (2023)
The AurkA kinase is a well-known mitotic regulator, frequently overexpressed in tumors. The microtubule-binding protein TPX2 controls AurkA activity, localization, and stability in mitosis. Non-mitotic roles of AurkA are emerging, and increased nuclear localization in interphase has been correlated with AurkA oncogenic potential. Still, the mechanisms leading to AurkA nuclear accumulation are poorly explored. Here, we investigated these mechanisms under physiological or overexpression conditions. We observed that AurkA nuclear localization is influenced by the cell cycle phase and nuclear export, but not by its kinase activity. Importantly, AURKA overexpression is not sufficient to determine its accumulation in interphase nuclei, which is instead obtained when AURKA and TPX2 are co-overexpressed or, to a higher extent, when proteasome activity is impaired. Expression analyses show that AURKA, TPX2, and the import regulator CSE1L are co-overexpressed in tumors. Finally, using MCF10A mammospheres we show that TPX2 co-overexpression drives protumorigenic processes downstream of nuclear AurkA. We propose that AURKA/TPX2 co-overexpression in cancer represents a key determinant of AurkA nuclear oncogenic functions.
Keyphrases
  • cell cycle
  • transcription factor
  • cell proliferation
  • binding protein
  • poor prognosis
  • small molecule
  • long non coding rna
  • high resolution
  • lymph node metastasis
  • protein protein
  • squamous cell